Summer Street Adjusts Model, Lifts PT on Ligand (LGND) to $79 Following Q4 Numbers
Tweet Send to a Friend
Summer Street is boosting its price target on Ligand Pharmaceuticals (Nasdaq: LGND) from $69 up to $78 following Q4 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
